Your prediction
ALS Ltd Stock
The ALS Ltd stock is trending slightly upwards today, with an increase of €0.10 (0.810%) compared to yesterday's price.
Pros and Cons of ALS Ltd in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | 0.810% | 0.000% | 0.000% | 37.430% | 37.430% | 61.842% | 106.723% |
| Seek Ltd | - | -0.758% | -4.380% | -3.676% | -3.676% | -1.504% | -26.404% |
| Downer EDI Ltd | 0.910% | -0.452% | 1.382% | 41.026% | 41.026% | 88.034% | 31.737% |
| Insperity Inc. | 0.610% | -1.212% | 8.667% | -55.034% | -55.034% | -69.245% | -49.846% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important